Merck (NYSE: MRK), known as MSD outside the United States and Canada,
announced today early study findings demonstrating an overall response
rate of 18.5 percent with KEYTRUDA, the company’s anti-PD-1 therapy, as
assessed by RECIST v1.1, central review (n=5/27), in PD-L1 positive,
advanced triple-negative breast cancer – one of the most aggressive
forms of breast cancer.
for Data Investigating KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Patients with Advanced Triple-Negative Breast Cancer Presented at 2014 San Antonio Breast Cancer Symposium investment picks